view on-demand
Hypromellose (HPMC) is a commonly used matrix former in controlled release tablet formulations. Generally used at levels greater than 20%, HPMC can have a significant impact on physical and functional characteristics (i.e., release profile and stability) of a matrix tablet. In this webinar our experts will address the challenges faced in high-speed tablet operations and how benecel™ xrf hpmc is designed specifically for this application. We will cover fundamental and advanced properties of HPMC with respect to ensuring optimal properties for your tablet formulation.
As regulatory focus on nitrosamines is increasing, we will also discuss formulation strategies to minimize nitrosamine formation in oral matrices and how Ashland’s low nitrite benecel™ hpmc can help formulators reduce NDMA levels in their drug products. As an excipient manufacturer focused on quality, we will share our efforts to reduce nitrite levels and how we can assure these levels in benecel™ hpmc product line.
We will demonstrate how collaborating with Ashland can offer you security of supply for HPMC, as we manufacture the polymers, distribute and deliver globally, and continue to invest in capacity increase.
key learning objectives:
presenter information:
Dr. Christian Mühlenfeld
head of Life Sciences R&D Europe, Middle East & Africa at Ashland
Dr Christian Mühlenfeld has extensive experience in a wide range of technologies including polymer science, immediate and modified release products, bioavailability enhancement and drug stabilization, as well as 3D printing and continuous manufacturing for solid dosage forms. He is author and co-author of several scientific publications and book chapters and has served on European Pharmacopeia expert committees for 5 years, dedicated to improving global health through setting pharmaceutical standards; presently serving as chair on the Cellulose Ethers Expert Committee. Christian is based in Dusseldorf, Germany.
©, Ashland. All rights reserved.
